{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-104020","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.965029+00:00","generated_at":"2026-05-17T19:05:11.481453+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Assembly Bio reports Q2 net loss $10.2M; ABI-6250 shows 4-day half-life supporting once-daily dosing","bullets":["Net loss $10.2M ($1.33/share) vs $11.2M ($1.98/share) in Q2 2024; revenue from Gilead collaboration $9.6M.","Cash $75.0M as of June 30, 2025, projected to fund operations into mid-2026.","ABI-6250 Phase 1a interim: mean half-life ~4 days supports once-daily oral dosing; dose-dependent bile acid elevations show NTCP target engagement.","Safety: all AEs grade 1-2; one grade 2 ALT elevation at highest single dose (25 mg), self-limited, no serious AEs.","Phase 1b herpes data (ABI-5366, ABI-1179) on track for fall 2025; positive Phase 1b data for ABI-4334 (HBV) reported earlier."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-104020","json":"https://secwatch.observer/filing/0000950170-25-104020.json","markdown":"https://secwatch.observer/filing/0000950170-25-104020.md","text":"https://secwatch.observer/filing/0000950170-25-104020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017025104020/0000950170-25-104020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017025104020/asmb-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:05:11.481453+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}